Johnson & Johnson’s MedTech segment saw its worldwide operational sales grow 5.4% year over year in 2025, reaching about $33.8 billion, the company said in a Wednesday (Jan. 21) earnings release.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — n ...

Johnson & Johnson’s MedTech segment saw its worldwide operational sales grow 5.4% year over year in 2025, reaching about $33.8 billion, the company said in a Wednesday (Jan. 21) earnings release.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — n ...

Johnson & Johnson (JNJ) reported $24.56 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 9.1%. EPS of $2.46 for the same period compares to $2.04 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $24.12 billion, representing a surprise of +1.84%. The company delivered an EPS surprise of +1.05%, with the consensus EPS estimate being $2.43.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings ...

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.46 per share, beating the Zacks Consensus Estimate of $2.43 per share. This compares to earnings of $2.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +1.05%. A quarter ago, it was expected that this world's biggest maker of health care products would post earnings of $2.77 per share when it actually produced earnings of $2.8, delivering a surprise of +1.08%.Ove ...

Core Viewpoint - Johnson & Johnson has provided a sales and profit guidance for the current year that surpasses Wall Street expectations, despite anticipating a significant financial impact from a recent drug pricing agreement with the U.S. government [1][3]. Group 1: Financial Guidance - The company expects current-year sales to be between $100 billion and $101 billion, exceeding consensus estimates of $98.88 billion [4]. - Full-year earnings are projected to be between $11.43 and $11.63 per share, compared to expectations of $11.45 [4]. Group 2: Recent Developments - Johnson & Johnson agreed to lower drug prices for U.S. consumers in exchange for exemptions from broad tariffs, aligning with actions taken by other major pharmaceutical companies [2]. - This initiative is part of broader efforts by the U.S. government to reduce drug costs, particularly in the lead-up to the midterm elections [2]. Group 3: Financial Performance - For the fourth quarter, the company reported revenue of $24.56 billion, reflecting a year-over-year increase of 9.1% and surpassing projections of $24.15 billion [4]. - The strong performance was driven by high demand for medical technology products and a 27% increase in sales of the Darzalex blood cancer treatment [4]. Group 4: Earnings Performance - Adjusted earnings per share reached $2.46, exceeding analyst estimates of $2.04, despite a decline in sales of the psoriasis drug Stelara due to rising biosimilar competition [5].

The fourth quarter earnings season is picking up speed. After several big banks reported last week, more financials will deliver results, with reports from Charles Schwab (SCHW) and regional banks like Fifth Third (FITB) on the schedule. But the attention will likely shift to Netflix (NFLX) and Intel (INTC), headlining the earnings calendar. An optimistic consensus is forming: As of Jan. 16, 7% of S&P 500 (^GSPC) companies have reported fourth quarter results, according to FactSet data, and Wall Street ...

Core Insights - Johnson & Johnson (JNJ) reported earnings per share of $2.46, exceeding estimates of $2.43, and revenue of approximately $24.56 billion, surpassing the estimated $24.16 billion [1][5] Group 1: Financial Performance - The company's revenue increased by 9% during the fourth quarter, driven primarily by its cancer and autoimmune drug segments [2][5] - JNJ is positioned to potentially reach $100 billion in revenue next year as part of a new strategic initiative [2] - Despite a drug pricing deal with the Trump administration expected to impact profits by "hundreds of millions of dollars," JNJ remains optimistic about its 2026 sales and profit projections [2] Group 2: Financial Metrics - JNJ has a price-to-earnings (P/E) ratio of approximately 21.10, indicating the price investors are willing to pay for each dollar of earnings [3][5] - The price-to-sales ratio is about 5.71, reflecting the value placed on each dollar of sales [3][5] - The enterprise value to sales ratio stands at around 6.00, suggesting the company's total valuation relative to its sales [3] - The enterprise value to operating cash flow ratio is approximately 22.86, showing how the company's valuation compares to its cash flow from operations [4] - JNJ has an earnings yield of about 4.74%, providing a return on investment for shareholders [4] - The company's debt-to-equity ratio is approximately 0.58, indicating a moderate level of debt relative to equity [4] - A current ratio of around 1.07 suggests JNJ's ability to cover short-term liabilities with short-term assets [4]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

After Tuesday's sharp sell-off, triggered by renewed fears of potential U.S. tariffs on Europe tied to President Donald Trump's stance on Greenland, Wall Street attempted a cautious rebound in Wednesday's session. • Lucid Group stock is showing exceptional strength. What’s behind LCID gains?Speaking at the World Economic Forum in Davos, Trump reiterated that acquiring Greenland remains a national security priority for the U.S. He said he expects NATO allies to understand the strategic importance of the issu ...

Every weekday, the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Wednesday 's key moments. 1. Stocks rose Wednesday following President Donald Trump's address at the World Economic Forum, where he eased investor concerns by saying the U.S. wouldn't use force to acquire Greenland. "We had a remarkable resurgence [this morning]," said Jim Cramer, but he added the rally is being led by "the wrong tech," pointing to Micron , which is heavily tied to ...